PHASE II STUDY OF INTERMITTENT ERLOTINIB (E) PLUS CARBOPLATIN (C), PACLITAXEL (P) AND BEVACIZUMAB (B) AS FRONTLINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): AVAFAST STUDY

被引：0
|
作者：
Cobo Dols, Manuel A. [1 ]
Blanco, Esperanza [2 ]
Bernabe, Reyes [3 ]
Fernandez, Inmaculada [4 ]
Inoriza, Angel [5 ]
Laura Ortega, Ana [6 ]
Valdivia, Javier [7 ]
机构：
[1] Hru Carlos Haya, Malaga, Spain
[2] Hosp Infanta Cristina, Badajoz, Spain
[3] Hosp Nuestra Senora De Valme, Seville, Spain
[4] Hosp De Jerez, Cadiz, Spain
[5] Hosp Juan Ramon Jimenez, Huelva, Spain
[6] Complejo Hosp De Jaen, Jaen, Spain
[7] Hosp Univ Virgen Nieves, Granada, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
ADVANCED NSCLC; Intermittent Erlotinib; Clinical Trial in Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-052
引用
收藏
页码：S1213 / S1213
页数：1
相关论文
共 50 条
  • [1] BEVACIZUMAB (B), CISPLATIN (C) AND PEMETREXED (P) PLUS MAINTENANCE B IN CHEMO-NAiVE PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): A PHASE II STUDY
    Lopez Vivanco, G.
    Carrera Revilla, S.
    Sancho Gutierrez, A.
    Marrodan Ciordia, I.
    Azkona Uribelarrea, E.
    Iruarrizaga Ovejas, E.
    Rubio Etxebarria, I.
    Cardona, J. V.
    Munoz Llerena, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S72 - S72
  • [2] ERLOTINIB AS FRONTLINE TREATMENT FOR ELDERLY PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): GGCP044/09 STUDY
    Firvida, J. L.
    Vazquez, S.
    Casal, J.
    Alonso, M.
    Varela, S.
    Villanueva, M. J.
    Afonso, F. J.
    Fernandez, O.
    Areses, C.
    Campos, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 436 - 436
  • [3] ERLOTINIB AS FRONTLINE TREATMENT FOR ELDERLY PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): GGCP044/09 STUDY
    Firvida Perez, J. L.
    Vazquez Estevez, S.
    Casal Rubio, J.
    Alonso Bermejo, M.
    Varela Ferreiros, S.
    Villanueva Silva, M. J.
    Afonso Afonso, J.
    Fernandez Calvo, O.
    Areses, K.
    Campos Balea, B.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S71 - S71
  • [4] Randomized phase II study comparing cisplatin plus pemetrexed plus bevacizumab with carboplatin plus paclitaxel plus bevacizumab in treatment-naive advanced non-squamous non-small cell lung cancer (CLEAR study)
    Koyama, R.
    Udagawa, H.
    Sugiyama, E.
    Komuta, K.
    Mori, M.
    Yokoyama, T.
    Sasaki, T.
    Saito, H.
    Ishida, H.
    Nakagawa, H.
    Sekine, A.
    Tamura, A.
    Shingyoji, M.
    Mizuno, K.
    Nakamura, A.
    Kinoshita, A.
    Yamanaka, T.
    Goto, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer
    Waples, J. M.
    Auerbach, M.
    Boccia, R.
    Wiggans, R. G.
    Steis, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer
    Ciuleanu, T.
    Tsai, C. -M.
    Tsao, C. -J.
    Milanowski, J.
    Amoroso, D.
    Heo, D. S.
    Groen, H. J. M.
    Szczesna, A.
    Chung, C. -Y.
    Chao, T. -Y.
    Middleton, G.
    Zeaiter, A.
    Klingelschmitt, G.
    Klughammer, B.
    Thatcher, N.
    LUNG CANCER, 2013, 82 (02) : 276 - 281
  • [7] Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC)
    Akerley, W. L.
    Rich, N. T.
    Egbert, L.
    Harker, W. G.
    Van Duren, T.
    Smit, J.
    Hoffman, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
    Guarino, Michael J.
    Masters, Gregory A.
    Biggs, David D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
  • [9] Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer
    Takiguchi, Yuichi
    Iwasawa, Shunichiro
    Minato, Koichi
    Miura, Yosuke
    Gemma, Akihiko
    Noro, Rintaro
    Yoshimori, Kozo
    Shingyoji, Masato
    Hino, Mitsunori
    Ando, Masahiro
    Okamoto, Hiroaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 659 - 667
  • [10] E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Stevenson, James
    Sulecki, Matthew Gerard
    Hugec, Vladimir
    Choong, Nicholas W.
    Saltzman, Joel N.
    Song, Wei
    Hansen, Richard M.
    Evans, Tracey L.
    Ramalingam, Suresh S.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345